Acorda Therapeutics (ACOR) Tops Q3 EPS by 16c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/17/2026

1. GNK
2. SPY
3. AZN
4. GSAT
5. S
6. HIVE
7. ALH
8. SERV
9. RDDT
10. CRGO

Go back to Acorda Therapeutics (ACOR) Tops Q3 EPS by 16c

Acorda Provides Financial and Pipeline Update for 2015 Third Quarter

October 22, 2015 6:00 AM EDT

AMPYRA® (dalfampridine) 3Q 2015 Net Revenue of $117.0 Million; 21% increase over 3Q 2014 Raising Full Year 2015 Guidance for AMPYRA Net Revenue from $410-$420 Million to $420-$430 Million Company Remains Cash Flow Positive While Funding Late Stage Pipeline

ARDSLEY, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc. (Nasdaq:ACOR) today provided a financial and pipeline update for the third... More